Abstract

The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer.

Keywords

MedicineConfidence intervalBreast cancerInternal medicineOncologyTamoxifenProportional hazards modelRelative riskCancerEstrogen receptorProspective cohort studyLymph nodeGynecologyGastroenterology

Affiliated Institutions

Related Publications

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.

Bernard Fisher , Carol Redmond , S Legault-Poisson +7 more

The National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted a randomized clinical trial to determine whether tamoxifen (TAM) plus chemotherapy is more effective th...

1990 Journal of Clinical Oncology 294 citations

Publication Info

Year
2004
Type
article
Volume
351
Issue
27
Pages
2817-2826
Citations
6215
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

6215
OpenAlex

Cite This

Soonmyung Paik, Steven Shak, Gong Tang et al. (2004). A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. New England Journal of Medicine , 351 (27) , 2817-2826. https://doi.org/10.1056/nejmoa041588

Identifiers

DOI
10.1056/nejmoa041588